Assignee
TILLOTTS PHARMA AG
CH·33 granted patents·14 pending applications·826 citations·filing 1991–2025
Top patents by PatentIndex Score
47 records- 0194US5972310AAqueous foamable compositionTILLOTTS PHARMA AG·Filed 1998·Granted Oct 26, 1999·143 cites·68 claims
- 0293US11534406B2Delayed release drug formulationTILLOTTS PHARMA AG·Filed 2020·Granted Dec 27, 2022·3 cites·27 claims
- 0393US5792795ATreatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acidsTILLOTTS PHARMA AG·Filed 1996·Granted Aug 11, 1998·155 cites·17 claims
- 0493US5541170AOrally administrable pharmaceutical compositionsTILLOTTS PHARMA AG·Filed 1995·Granted Jul 30, 1996·113 cites·7 claims
- 0592US5759520AAqueous foamable compositionTILLOTTS PHARMA AG·Filed 1995·Granted Jun 2, 1998·112 cites·49 claims
- 0691US5948818ATreatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acidsTILLOTTS PHARMA AG·Filed 1998·Granted Sep 7, 1999·140 cites·13 claims
- 0789US5541171AOrally administrable pharmaceutical compositionTILLOTTS PHARMA AG·Filed 1995·Granted Jul 30, 1996·79 cites·19 claims
- 0888US10226430B2Delayed release drug formulationTILLOTTS PHARMA AG·Filed 2013·Granted Mar 12, 2019·10 cites·33 claims
- 0987US11517534B2Delayed release drug formulationTILLOTTS PHARMA AG·Filed 2017·Granted Dec 6, 2022·2 cites·31 claims
- 1087US11266605B2Modified release coated capsulesTILLOTTS PHARMA AG·Filed 2015·Granted Mar 8, 2022·3 cites·14 claims
- 1186US11459383B2Anti-TNF-alpha-antibodies and functional fragments thereofTILLOTTS PHARMA AG·Filed 2017·Granted Oct 4, 2022·5 cites·20 claims
- 1286US10272048B2Delayed release drug formulationTILLOTTS PHARMA AG·Filed 2016·Granted Apr 30, 2019·4 cites·7 claims
- 1386US9814681B2Delayed release drug formulationTILLOTTS PHARMA AG·Filed 2013·Granted Nov 14, 2017·6 cites·46 claims
- 1486US9364440B2Delayed release drug formulationTILLOTTS PHARMA AG·Filed 2013·Granted Jun 14, 2016·8 cites·50 claims
- 1581US11472872B2Antibody variantsTILLOTTS PHARMA AG·Filed 2018·Granted Oct 18, 2022·2 cites·13 claims
- 1679US12209122B2Anti-TNF-alpha-antibodies and functional fragments thereofTILLOTTS PHARMA AG·Filed 2022·Granted Jan 28, 2025·0 cites·26 claims
- 1775US10391061B2Delayed release pharmaceutical formulation and methods of making and using sameTILLOTTS PHARMA AG·Filed 2018·Granted Aug 27, 2019·2 cites·13 claims
- 1875US2025122275A1Antibody variantsTILLOTTS PHARMA AG·Filed 2024·Application pending·0 cites
- 1974US12043663B2Anti-TNF-alpha-antibodies and functional fragments thereofTILLOTTS PHARMA AG·Filed 2022·Granted Jul 23, 2024·0 cites·16 claims
- 2074US10799515B2Delayed release drug formulationTILLOTTS PHARMA AG·Filed 2013·Granted Oct 13, 2020·1 cites·50 claims
- 2173US5843482AProducts and processes for the treatment of the alimentary canalTILLOTTS PHARMA AG·Filed 1991·Granted Dec 1, 1998·26 cites·21 claims
- 2272US2024343793A1Antibody variantsTILLOTTS PHARMA AG·Filed 2024·Application pending·0 cites
- 2369US2025127722A1Solid oral dosage form comprising antibodies for sustained release in the lower gastrointestinal tractTILLOTTS PHARMA AG·Filed 2024·Application pending·0 cites
- 2468US2024000714A1Topical treatment of inflammatory bowel disease using antibodies and fragments thereofTILLOTTS PHARMA AG·Filed 2023·Application pending·0 cites
- 2567US11998641B2Modified release coated capsulesTILLOTTS PHARMA AG·Filed 2021·Granted Jun 4, 2024·0 cites·10 claims
- 2667US9895314B2Delayed release pharmaceutical formulation containing porous carrier particles for colon targetingTILLOTTS PHARMA AG·Filed 2014·Granted Feb 20, 2018·1 cites·12 claims
- 2767US2025051431A2Antibody VariantsTILLOTTS PHARMA AG·Filed 2022·Application pending·0 cites
- 2865US12370147B2Coatable core for a modified release drug formulationTILLOTTS PHARMA AG·Filed 2019·Granted Jul 29, 2025·0 cites·12 claims
- 2961US11717484B2Topical treatment of inflammatory bowel disease using antibodies and fragments thereofTILLOTTS PHARMA AG·Filed 2018·Granted Aug 8, 2023·0 cites·13 claims
- 3061US2024099980A1Preparation of solid dosage forms comprising antibodies by solutions/suspension layeringTILLOTTS PHARMA AG·Filed 2023·Application pending·0 cites
- 3160US11999781B2Antibody variantsTILLOTTS PHARMA AG·Filed 2018·Granted Jun 4, 2024·0 cites·5 claims
- 3260US2025302755A1Coatable core for a modified release drug formulationTILLOTTS PHARMA AG·Filed 2025·Application pending·0 cites
- 3357US12215146B2Antibody variantsTILLOTTS PHARMA AG·Filed 2018·Granted Feb 4, 2025·0 cites·5 claims
- 3454US6217897B1Oral mucosal composition comprising 5-aminosalicylic acidTILLOTTS PHARMA AG·Filed 1997·Granted Apr 17, 2001·11 cites·9 claims
- 3553US2022016037A1Colonic drug delivery formulationTILLOTTS PHARMA AG·Filed 2019·Application pending·0 cites
- 3650US11826470B2Preparation of solid dosage forms comprising antibodies by solution/suspension layeringTILLOTTS PHARMA AG·Filed 2018·Granted Nov 28, 2023·0 cites·24 claims
- 3748US12370146B2Method of producing a delayed release drug formulationTILLOTTS PHARMA AG·Filed 2019·Granted Jul 29, 2025·0 cites·20 claims
- 3848US2016287521A1Multi-particulate drug delivery systemTILLOTTS PHARMA AG·Filed 2014·Application pending·0 cites
- 3945US10975143B2Anti-TNF-α-antibodies and functional fragments thereofTILLOTTS PHARMA AG·Filed 2017·Granted Apr 13, 2021·0 cites·20 claims
- 4045US10179105B2Microgel particles containing nanotubes loaded with an active pharmaceutical ingredientTILLOTTS PHARMA AG·Filed 2016·Granted Jan 15, 2019·0 cites·12 claims
- 4145US2022016038A1Colonic drug delivery formulationTILLOTTS PHARMA AG·Filed 2019·Application pending·0 cites
- 4242US11160762B2Modified release coated capsulesTILLOTTS PHARMA AG·Filed 2015·Granted Nov 2, 2021·0 cites·12 claims
- 4337US2022119515A1Topical treatment of immune checkpoint inhibitor induced diarrhoea, colitis or enterocolitis using antibodies and fragments thereofTILLOTTS PHARMA AG·Filed 2019·Application pending·0 cites
- 4433US12419843B2Method for preparing a solid dosage form comprising antibodies by wet granulation, extrusion and spheronizationTILLOTTS PHARMA AG·Filed 2018·Granted Sep 23, 2025·0 cites·16 claims
- 4532US2007219271A1Pharmaceutical Compositions Containing Pufa And At Least One Of An Immunosuppressive Agent Or An Antineoplastic AgentTILLOTTS PHARMA AG·Filed 2005·Application pending·0 cites
- 4632US2009018125A1Pharmaceutical Composition and Its UseTILLOTTS PHARMA AG·Filed 2005·Application pending·0 cites
- 4731US2019336449A1Multiple unit dosage form comprising a core with individual core units covered by a mucoadhesive material and an enteric core coatingTILLOTTS PHARMA AG·Filed 2017·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when TILLOTTS PHARMA AG files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →